Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Diabetologica
Published in: Acta Diabetologica 3/2020

01-03-2020 | Insulins | Review Article

Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review

Authors: Monica Finessi, Gianni Bisi, Désirée Deandreis

Published in: Acta Diabetologica | Issue 3/2020

Login to get access

Abstract

Positron emission tomography/computed tomography (PET/CT) is a standard procedure for imaging cancer commonly used in the clinical practice for several diseases, in particular for cancer staging, restaging, treatment monitoring and radiation therapy planning. Despite the availability of many radiotracers, 18F-fluoro-2-deoxy-2-d-glucose ([18F]FDG) is the most used. International PET/CT guidelines propose protocols for patients’ correct preparation before [18F]FDG injection, in particular with the regard of diabetic patients and therapy management. Hyperglycemic conditions and oral or insulin medication showed advantages and disadvantages on PET/CT scan accuracy: A correct knowledge of effects of these conditions on glucose metabolism assumes a fundamental role on patients management before [18F]FDG PET/CT scan.
Literature
1.
Gallamini A, Zwarthoed C, Borra A (2014) Positron emission tomography in oncology. Cancers (Basel) 6:1821–1889
2.
Ido T, Wan C, Casella J et al (1978) Labeled 2-deoxy-d-glucose analogs: 18F labeled 2-deoxy-2-fluoro-d-glucose, 2-deoxy-2-fluoro-d-mannose and 14C-2-deoxy-2-fluoro-d-glucose. J Label Compd Radiopharm 14:175–183
3.
Warburg OP, Negelein E (1924) Uber den stoffwechsel der carcinomzelle. Biochem Z 152:309–335
4.
5.
Chen Z, Liu M, Li L, Chen L (2017) Involvement of the Warburg effect in non-tumor diseases processes. J Cell Physiol 2017:2839–2849
6.
Larson SM (2006) 18 F-FDG imaging: molecular or functional? J Nucl Med 47:31N–32N
7.
Pauwels E, Sturm E, Bombardieri E, Cleton F, Stokkel M (2000) Positron-emission tomography with [18F]fluoro-deoxy glucose, part 1. Biochemical uptake mechanism and its implication for clinical studies. J Cancer Res Clin Oncol 126:549–559PubMed
8.
Theorens B, Sarkar H, Kaback H, Lodish H (1988) Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells. Cell 55:281–290
9.
Maher F (1995) Immunolocalization of GLUT1 and GLUT3 glucose transporters inprimary cultured neurons and glia. J Neurosci Res 42:459–469PubMed
10.
Rea S, James D (1997) Moving GLUT4: the biogenesis and trafficking of GLUT4 storage vesicles. Diabetes 46:1667–1677PubMed
11.
Kayano T, Burant C, Fukumoto H, Gould G, Fan Y, Eddy R et al (1990) Human facilitative glucose transporters. Isolation, functional characterization, and gene localization of cDNAs encoding an isoform (GLUT5) expressed in small, and adipose tissue and an unusual glucose transporter pseudogene-like sequence (GLUT6). J Biol Chem 265:13276–13282PubMed
12.
Brown R, Wahl R (1993) Over expression of glut-1 glucose transporter in human breast cancer: an immunohistochemical study. Cancer 72:2979–2985PubMed
13.
Kubota R, Yamada S, Kubota K, Ishiwata K, Tamahashi N, Ido T (1992) Fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 33(11):1972–1980PubMed
14.
Mochizuki T, Tsukamoto E, Kuge Y, Kanegae K, Zhao S, Hikosaka K et al (2001) FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 42(10):1551–1555PubMed
15.
16.
Jamar F, Buscombe J, Chiti A, Christian P, Delbeke D, Donohoe K et al (2013) EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med 54(4):647–658PubMed
17.
Randle P, Garland P, Hales C, Newsholme E (1963) The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1(7285):785–789PubMed
18.
19.
Moran JK, Lee HB, Blaufox MD (1999) Optimization of urinary FDG excretion during PET imaging. J Nucl Med 40(8):1352–1357PubMed
20.
Qiao H, Bai J, Chen Y, Tian J (2007) Kidney modelling for FDG excretion with PET. Int J Biomed Imaging 2007:1–4
21.
Rosica D, Cheng SC, Hudson M, Sakellis C, Van Den Abbeele AD, Kim CK et al (2018) Effects of hyperglycemia on fluorine-18-fluorodeoxyglucose biodistribution in a large oncology clinical practice. Nucl Med Commun 39(5):417–422PubMed
22.
Wahl R, Henry C, Ethier S (1992) Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-d-glucose in rodents with mammary carcinoma. Radiology 183:643–647PubMed
23.
Diederichs C, Staib L, Glatting G, Beger H, Reske S (1998) FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39:1030–1033PubMed
24.
Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354:496–507PubMed
25.
Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl_1):122S–150SPubMedPubMedCentral
26.
Barrington SF, Kluge R (2017) FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas. Eur J Nucl Med Mol Imaging 44(Suppl 1):S97–S110
27.
Sprinz C, Zanon M, Altmayer S, Watte G, Irion K, Marchiori E et al (2018) Effects of blood glucose level on 18F fluorodeoxyglucose (18F-FDG) uptake for PET/CT in normal organs: an analysis on 5623 patients. Sci Rep 8(1):6–11
28.
29.
Eskian M, Alavi A, Khorasanizadeh M, Viglianti BL, Jacobsson H (2019) Effect of blood glucose level on standardized uptake value (SUV) in 18 F-FDG PET-scan: a systematic review and meta-analysis of 20, 807 individual SUV measurements. Eur J Nucl Med Mol Imaging 46:224–237PubMed
30.
Yang J, Wen J, Tian T, Lu Z, Wang Y, Wang Z et al (2017) GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget 8(7):11788–11796PubMed
31.
Macheda ML, Rogers S, Best JD (2005) Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 202(3):654–662PubMed
32.
Carvalho K, Cunha I, Rocha R, Ayala F, Cajaiba M, Begnami M et al (2011) GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 66:965–972
33.
Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Någren K et al (2009) EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging 36(12):2103–2110PubMed
34.
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W et al (2014) FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328–354PubMedPubMedCentral
35.
Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA et al (2006) Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med 47(5):885–895PubMed
36.
37.
Shankar L, Hoffman J, Bacharach S et al (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47:1059–1066PubMed
38.
39.
Martin J, Saleem N (2014) 18F-FDG PET-CT scanning and diabetic patients: what to do? Nucl Med Commun 35(12):1197–1203PubMed
40.
41.
Gontier E, Fourme E, Wartski M, Blondet C, Bonardel G, Le Stanc E et al (2008) High and typical 18F-FDG bowel uptake in patients treated with metformin. Eur J Nucl Med Mol Imaging 35(1):95–99PubMed
42.
Lee SH, Jin S, Lee HS, Ryu JS, Lee JJ (2016) Metformin discontinuation less than 72 h is suboptimal for F-18 FDG PET/CT interpretation of the bowel. Ann Nucl Med 30(9):629–636PubMed
43.
Oh JR, Song HC, Chong A, Ha JM, Jeong SY, Min JJ et al (2010) Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. Am J Roentgenol 195(6):1404–1410
44.
Huang S, Czech MP (2007) The GLUT4 glucose transporter. Cell Metab 5(4):237–252PubMed
45.
Bryant NJ, Govers R, James DE (2002) Regulated transport of the glucose transporter GLUT4. Nat Rev Mol Cell Biol 3(4):267–277PubMed
46.
47.
Turcotte E, Leblanc M, Carpentier A, Bénard F (2006) Optimization of whole-body positron emission tomography imaging by using delayed 2-deoxy-2-[F-18]fluoro-d-glucose injection following I. V. insulin in diabetic patients. Mol Imaging Biol 8(6):348–354PubMed
48.
49.
Caobelli F, Pizzocaro C, Paghera B, Guerra UP (2013) Proposal for an optimized protocol for intravenous administration of insulin in diabetic patients undergoing 18F-FDG PET/CT. Nucl Med Commun 34(3):271–275PubMed
50.
Song HS, Yoon JK, Lee SJ, Yoon SH, Jo KS, An YS (2013) Ultrashort-acting insulin may improve on18F-FDG PET/CT image quality in patients with uncontrolled diabetic mellitus. Nucl Med Commun 34(6):527–532PubMed
51.
Garcia JR, Sanchis A, Juan J, Tomas J, Domenech A, Soler M et al (2014) Influence of subcutaneous administration of rapid-acting insulin in the quality of 18F-FDG PET/CT studies. Nucl Med Commun 35(5):459–465PubMed
Metadata
Title
Hyperglycemia and 18F-FDG PET/CT, issues and problem solving: a literature review
Authors
Monica Finessi
Gianni Bisi
Désirée Deandreis
Publication date
01-03-2020
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 3/2020
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01385-8

Other articles of this Issue 3/2020

Acta Diabetologica 3/2020 Go to the issue

Letter to the Editor

Reply to Letter to the editor regarding “The ZJU index is a powerful index for identifying NAFLD in the general Chinese population”

Letter to the Editor

Letter to the editor regarding “The ZJU index is a powerful index for identifying NAFLD in the general Chinese population”

Original Article

Diabetic macular edema with neuroretinal detachment: OCT and OCT-angiography biomarkers of treatment response to anti-VEGF and steroids

Original Article

Trend 2010–2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy

Original Article

Mini-doses of glucagon to prevent hypoglycemia in children with type 1 diabetes refusing food: a case series

Original Article

Circulating miR-103 family as potential biomarkers for type 2 diabetes through targeting CAV-1 and SFRP4
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits